Scientists from the European Union (EU) and researchers from Sanofi-Aventis SA have developed the first human vaccine against the H7N1 avian influenza virus, a strain that can be transmitted from birds to humans.
In a statement, the European Commission clarified that H7 is less likely to mutate into a pandemic influenza virus strain like H5N1; however, research on this virus represents a valuable avenue for future vaccine development.
Meanwhile, China has announced the development of several vaccines, including one for H5N2, and will begin vaccinating poultry “in key areas.” Russia has issued a call for volunteers to participate in avian influenza vaccine trials in November and December of this year, offering compensation of 200 euros per person. The United States has recently ordered $62 million worth of avian influenza vaccines from Chiron Corporation and previously signed a $100 million contract with Sanofi-Aventis.
THỦY TÙNG (According to Bloomberg, AP, Reuters, EUROPA)
